Jaguar Health, Inc.
28.7.2021 14:31:39 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, and member of the board of directors of Napo EU S.p.A., will be aired during an investor webcast tomorrow (Thursday, July 29, 2021) at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A., recently announced the closing of the financing of Dragon SPAC for gross proceeds of approximately 8,830,000 euros. The registration link for the webcast appears below.
Participation Instructions for Webcast
When: Thursday, July 29, 2021, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that an investor webcast will take place July 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/657270/REMINDER-FROM-JAGUAR-HEALTH-Innovators-with-Jane-King-Interview-with-Lisa-Conte-to-Air-During-Jaguar-Investor-Webcast-on-Thursday-July-29-2021-at-830-AM-Eastern-to-Provide-Business-Updates
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release
ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the
Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release
HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy
Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom